Download PDF
Semin Thromb Hemost 2009; 35(7): 630-643
DOI: 10.1055/s-0029-1242717
© Thieme Medical Publishers

Role of Thrombophilia in Adverse Obstetric Outcomes and Their Prevention Using Antithrombotic Therapy

Elvira Grandone1 , Michela Tomaiuolo1 , Donatella Colaizzo1 , Paul R.J Ames2 , Maurizio Margaglione1 , 3
  • 1Atherosclerosis and Thrombosis Unit, I.R.C.C.S. “Casa Sollievo dela Sofferenza,” S. Giovanni R. (FG), Italy
  • 2Department of Haematology, Royal Preston Hospital, Preston and Immunoclot Ltd, Leeds, United Kingdom
  • 3Medical Genetics, University of Foggia, Foggia, Italy
Further Information

Publication History

Publication Date:
09 December 2009 (online)

    Permissions and Reprints

ABSTRACT

A series of case-control studies in the last decade have shown the role of inherited thrombophilia in the occurrence of adverse obstetric outcomes. In small series of cases, it has been proven that rare inherited causes of thrombophilia such as natural anticoagulant deficiencies can be associated with fetal losses. The confirmed presence of antiphospholipid antibodies in plasma, representing an acquired thrombophilic condition, is also an established cause of fetal losses, although other studies with a smaller sample size have found an association with other obstetric complications, namely preeclampsia, fetal growth restriction, and abruption placentae. Case-control studies have been performed regarding the potential association between unexplained fetal losses and mild hyperhomocysteinemia. Although case-control and prospective studies are also available regarding hyperhomocysteinemia and other gestational vascular complications, published data are conflicting. Intervention studies have been performed to prevent adverse obstetric outcomes in women with inherited or acquired thrombophilia and previous adverse outcomes. There is much debate in the literature regarding the need for treatment of women with thrombophilia during pregnancy. Although in most cases these are not randomized controlled trials, all studies found significantly better outcomes in treated pregnancies compared with those of untreated pregnancies.

KEYWORDS

Thrombophilia - adverse pregnancy outcomes - prophylaxis

REFERENCES

  • 1 De Stefano V, Rossi E, Leone G. Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications.  Semin Vasc Med. 2003;  3(1) 47-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Ku D H, Arkel Y S, Paidas M P, Lockwood C J. Circulating levels of inflammatory cytokines (IL-1 beta and TNF-alpha), resistance to activated protein C, thrombin and fibrin generation in uncomplicated pregnancies.  Thromb Haemost. 2003;  90(6) 1074-1079
    PubMedGoogle Scholar
  • 3 Clark P, Brennand J, Conkie J A, McCall F, Greer I A, Walker I D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy.  Thromb Haemost. 1998;  79(6) 1166-1170
    PubMedGoogle Scholar
  • 4 Stirling Y, Woolf L, North W R, Seghatchian M J, Meade T W. Haemostasis in normal pregnancy.  Thromb Haemost. 1984;  52(2) 176-182
    PubMedGoogle Scholar
  • 5 Comp P C, Thurnau G R, Welsh J, Esmon C T. Functional and immunologic protein S levels are decreased during pregnancy.  Blood. 1986;  68(4) 881-885
    PubMedGoogle Scholar
  • 6 Hellgren M, Blombäck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition.  Gynecol Obstet Invest. 1981;  12(3) 141-154
    CrossrefPubMedGoogle Scholar
  • 7 Stirling Y, Woolf L, North W R, Seghatchian M J, Meade T W. Haemostasis in normal pregnancy.  Thromb Haemost. 1984;  52(2) 176-182
    PubMedGoogle Scholar
  • 8 Eichinger S, Weltermann A, Philipp K et al.. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.  Thromb Haemost. 1999;  82(4) 1232-1236
    PubMedGoogle Scholar
  • 9 Bremme K A. Haemostatic changes in pregnancy.  Best Pract Res Clin Haematol. 2003;  16(2) 153-168
    CrossrefPubMedGoogle Scholar
  • 10 Heit J A, Kobbervig C E, James A H, Petterson T M, Bailey K R, Melton III L J. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study.  Ann Intern Med. 2005;  143(10) 697-706
    CrossrefPubMedGoogle Scholar
  • 11 Grandone E, Margaglione M. Inherited thrombophilia and gestational vascular complications.  Best Pract Res Clin Haematol. 2003;  16(2) 321-332
    CrossrefPubMedGoogle Scholar
  • 12 Roberts J M, Taylor R N, Musci T J, Rodgers G M, Hubel C A, McLaughlin M K. Preeclampsia: an endothelial cell disorder.  Am J Obstet Gynecol. 1989;  161(5) 1200-1204
    PubMedGoogle Scholar
  • 13 Salafia C M, Pezzullo J C, López-Zeno J A, Simmens S, Minior V K, Vintzileos A M. Placental pathologic features of preterm preeclampsia.  Am J Obstet Gynecol. 1995;  173(4) 1097-1105
    CrossrefPubMedGoogle Scholar
  • 14 Shanklin D R, Sibai B M. Ultrastructural aspects of preeclampsia. I. Placental bed and uterine boundary vessels.  Am J Obstet Gynecol. 1989;  161(3) 735-741
    PubMedGoogle Scholar
  • 15 Rey E, Kahn S R, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis.  Lancet. 2003;  361(9361) 901-908
    CrossrefPubMedGoogle Scholar
  • 16 Kovalevsky G, Gracia C R, Berlin J A, Sammel M D, Barnhart K T. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis.  Arch Intern Med. 2004;  164(5) 558-563
    CrossrefPubMedGoogle Scholar
  • 17 Griffin J H, Evatt B, Zimmerman T S, Kleiss A J, Wideman C. Deficiency of protein C in congenital thrombotic disease.  J Clin Invest. 1981;  68(5) 1370-1373
    CrossrefPubMedGoogle Scholar
  • 18 Schwarz H P, Fischer M, Hopmeier P, Batard M A, Griffin J H. Plasma protein S deficiency in familial thrombotic disease.  Blood. 1984;  64(6) 1297-1300
    CrossrefPubMedGoogle Scholar
  • 19 De Stefano V, Finazzi G, Mannucci P M. Inherited thrombophilia: pathogenesis, clinical syndromes, and management.  Blood. 1996;  87(9) 3531-3544
    PubMedGoogle Scholar
  • 20 Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism—results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).  Thromb Haemost. 1997;  77(3) 444-451
    PubMedGoogle Scholar
  • 21 Friederich P W, Sanson B J, Simioni P et al.. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis.  Ann Intern Med. 1996;  125(12) 955-960
    CrossrefPubMedGoogle Scholar
  • 22 Han X, Fiehler R, Broze Jr G J. Characterization of the protein Z-dependent protease inhibitor.  Blood. 2000;  96(9) 3049-3055
    PubMedGoogle Scholar
  • 23 Paidas M J, Ku D H, Lee M J et al.. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications.  J Thromb Haemost. 2005;  3(3) 497-501
    CrossrefPubMedGoogle Scholar
  • 24 Gris J C, Quéré I, Dechaud H et al.. High frequency of protein Z deficiency in patients with unexplained early fetal loss.  Blood. 2002;  99(7) 2606-2608
    CrossrefPubMedGoogle Scholar
  • 25 Grandone E, Colaizzo D, Cappucci F, D'Ambrosio R L, Vecchione G, Margaglione M. An unreported mutation within protein Z gene is associated with very low protein levels in women with fetal loss.  Fertil Steril. 2008;  90(3) 864-865
    CrossrefPubMedGoogle Scholar
  • 26 Grandone E, Favuzzi G, De Stefano V et al.. Protein Z g-42a variant and the risk of pregnancy-related venous thromboembolism in a cohort of Italian patients.  Thromb Res. 2009;  123(6) 848-850
    CrossrefPubMedGoogle Scholar
  • 27 Chinni E, Tiscia G L, Colaizzo D, Vergura P, Margaglione M, Grandone E. Annexin V expression in human placenta is influenced by the carriership of the common haplotype M2.  Fertil Steril. 2009;  91(3) 940-942
    CrossrefPubMedGoogle Scholar
  • 28 Bogdanova N, Horst J, Chlystun M et al.. A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss.  Hum Mol Genet. 2007;  16(5) 573-578
    CrossrefPubMedGoogle Scholar
  • 29 Tiscia G, Colaizzo D, Chinni E et al.. Haplotype M2 in the annexin A5 (ANXA5) gene and the occurrence of obstetric complications.  Thromb Haemost. 2009;  102(3) 309-313
    PubMedGoogle Scholar
  • 30 Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy.  Thromb Res. 2009;  123(3) 482-487
    CrossrefPubMedGoogle Scholar
  • 31 Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment.  Semin Thromb Hemost. 2008;  34(3) 267-273
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Bates S M, Greer I A, Pabinger I, Sofaer S, Hirsh J. American College of Chest Physicians . Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, Suppl) 844S-886S
    CrossrefPubMedGoogle Scholar
  • 33 Macklon N S, Greer I A. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience.  Scott Med J. 1996;  41(3) 83-86
    PubMedGoogle Scholar
  • 34 James A H. Venous thromboembolism in pregnancy.  Arterioscler Thromb Vasc Biol. 2009;  29(3) 326-331
    CrossrefPubMedGoogle Scholar
  • 35 McColl M D, Ramsay J E, Tait R C et al.. Risk factors for pregnancy associated venous thromboembolism.  Thromb Haemost. 1997;  78(4) 1183-1188
    PubMedGoogle Scholar
  • 36 Grandone E, Margaglione M, Colaizzo D et al.. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations.  Am J Obstet Gynecol. 1998;  179(5) 1324-1328
    CrossrefPubMedGoogle Scholar
  • 37 Biron-Andreani C, Schved J F, Daures J P, Factor V. Factor V Leiden mutation and pregnancy-related venous thromboembolism: what is the exact risk? Results from a meta-analysis.  Thromb Haemost. 2006;  96(1) 14-18
    PubMedGoogle Scholar
  • 38 Robertson L, Wu O, Langhorne P et al.. Thrombophilia in pregnancy: a systematic review.  Br J Haematol. 2006;  132(2) 171-196
    CrossrefPubMedGoogle Scholar
  • 39 Lewis G 2007. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving mothers' lives: reviewing maternal deaths to make motherhood safer—2003–2005. In: The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. London, United Kingdom; CEMACH
    Google Scholar
  • 40 Brill-Edwards P, Ginsberg J S, Gent M Recurrence of Clot in This Pregnancy Study Group et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism.  N Engl J Med. 2000;  343(20) 1439-1444
    CrossrefPubMedGoogle Scholar
  • 41 Pabinger I, Grafenhofer H, Kyrle P A et al.. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism.  Blood. 2002;  100(3) 1060-1062
    CrossrefPubMedGoogle Scholar
  • 42 Stirrat G M. Recurrent miscarriage.  Lancet. 1990;  336(8716) 673-675
    CrossrefPubMedGoogle Scholar
  • 43 Ventura S J, Taffel S M, Mosher W D. Estimates of pregnancies and pregnancy rates for the United States, 1976–85.  Am J Public Health. 1988;  78(5) 506-511
    CrossrefPubMedGoogle Scholar
  • 44 Alberman E. The epidemiology of repeated abortion. In: Beard RW, Sharp F Early Pregnancy Loss: Mechanisms and Treatment. London, United Kingdom; RCOG Press 1988: 9-17
    PubMedGoogle Scholar
  • 45 De Braekeleer M, Dao T N. Cytogenetic studies in couples experiencing repeated pregnancy losses.  Hum Reprod. 1990;  5(5) 519-528
    PubMedGoogle Scholar
  • 46 Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases.  Hum Reprod. 1994;  9(7) 1328-1332
    PubMedGoogle Scholar
  • 47 Grimbizis G F, Camus M, Tarlatzis B C, Bontis J N, Devroey P. Clinical implications of uterine malformations and hysteroscopic treatment results.  Hum Reprod Update. 2001;  7(2) 161-174
    CrossrefPubMedGoogle Scholar
  • 48 Warburton D, Strobino B. Recurrent spontaneous abortion. In: Bennet MJ, Edmonds DK Spontaneous and Recurrent Abortion. Oxford, United Kingdom; Blackwell Scientific 1987: 77-78
    PubMedGoogle Scholar
  • 49 Sanson B J, Friederich P W, Simioni P et al.. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women.  Thromb Haemost. 1996;  75(3) 387-388
    PubMedGoogle Scholar
  • 50 Preston F E, Rosendaal F R, Walker I D et al.. Increased fetal loss in women with heritable thrombophilia.  Lancet. 1996;  348(9032) 913-916
    CrossrefPubMedGoogle Scholar
  • 51 Pattison N S, Chamley L W, McKay E J, Liggins G C, Butler W S. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations.  Br J Obstet Gynaecol. 1993;  100(10) 909-913
    PubMedGoogle Scholar
  • 52 Erkan D, Merrill J T, Yazici Y, Sammaritano L, Buyon J P, Lockshin M D. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin.  Arthritis Rheum. 2001;  44(6) 1466-1467
    CrossrefPubMedGoogle Scholar
  • 53 Gris J C, Perneger T V, Quéré I et al.. Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study.  Blood. 2003;  102(10) 3504-3513
    CrossrefPubMedGoogle Scholar
  • 54 Lynch A, Marlar R, Murphy J et al.. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study.  Ann Intern Med. 1994;  120(6) 470-475
    PubMedGoogle Scholar
  • 55 Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy.  Obstet Gynecol. 1995;  86(4 Pt 1) 555-559
    CrossrefPubMedGoogle Scholar
  • 56 Erkan D, Merrill J T, Yazici Y, Sammaritano L, Buyon J P, Lockshin M D. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin.  Arthritis Rheum. 2001;  44(6) 1466-1467
    CrossrefPubMedGoogle Scholar
  • 57 Wouters M G, Boers G H, Blom H J et al.. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss.  Fertil Steril. 1993;  60(5) 820-825
    PubMedGoogle Scholar
  • 58 Nelen W L, Blom H J, Steegers E A, den Heijer M, Eskes T K. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis.  Fertil Steril. 2000;  74(6) 1196-1199
    CrossrefPubMedGoogle Scholar
  • 59 Kujovich J L. Thrombophilia and pregnancy complications.  Am J Obstet Gynecol. 2004;  191(2) 412-424
    CrossrefPubMedGoogle Scholar
  • 60 Krause M, Sonntag B, Klamroth R et al.. Lipoprotein (a) and other prothrombotic risk factors in Caucasian women with unexplained recurrent miscarriage. Results of a multicentre case-control study.  Thromb Haemost. 2005;  93(5) 867-871
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Kupferminc M J, Eldor A, Steinman N et al.. Increased frequency of genetic thrombophilia in women with complications of pregnancy.  N Engl J Med. 1999;  340(1) 9-13
    CrossrefPubMedGoogle Scholar
  • 62 Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause.  Thromb Haemost. 1999;  82(1) 6-9
    PubMedGoogle Scholar
  • 63 Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss.  Hum Reprod. 2002;  17(6) 1633-1637
    CrossrefPubMedGoogle Scholar
  • 64 Lyall F, Greer I A. Pre-eclampsia: a multifaceted vascular disorder of pregnancy.  J Hypertens. 1994;  12(12) 1339-1345
    PubMedGoogle Scholar
  • 65 Magann E F, Martin Jr J N. Pre-clampsia/eclampsia. In: Knobil E, Neill JD Encyclopedia of Reproduction. Vol 3. San Diego, CA; Academic Press 1998: 964-970
    PubMedGoogle Scholar
  • 66 Saftlas A F, Olson D R, Franks A L, Atrash H K, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979–1986.  Am J Obstet Gynecol. 1990;  163(2) 460-465
    PubMedGoogle Scholar
  • 67 Cowles T, Saleh A, Cotton D B. Hypertensive disorders of pregnancy. In: James DK, Steer PJ, Weiner CP, Gonik B High Risk Pregnancy-Management Options. London, United Kingdom; Saunders 1994: 253-275
    PubMedGoogle Scholar
  • 68 Sibai B M. Hypertensive disease. In: Gleicher N Principle and Practice of Medicinal Therapy in Pregnancy. Stamford, CT; Appleton and Lange 1998: 997-1022
    PubMedGoogle Scholar
  • 69 Redman C W. Current topic: pre-eclampsia and the placenta.  Placenta. 1991;  12(4) 301-308
    CrossrefPubMedGoogle Scholar
  • 70 Redman C W. Platelets and the beginnings of preeclampsia.  N Engl J Med. 1990;  323(7) 478-480
    CrossrefPubMedGoogle Scholar
  • 71 Greer I A. Pathological processes in pregnancy-induced hypertension and intrauterine growth retardation: “an excess of heated blood”. In: Greer IA, Turpie AGG, Forbes CD Haemostasis and Thrombosis in Obstetrics and Gynaecology. London, United Kingdom; Chapman and Hall 1992: 163-202
    PubMedGoogle Scholar
  • 72 Dizon-Townson D S, Nelson L M, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia.  Am J Obstet Gynecol. 1996;  175(4 Pt 1) 902-905
    CrossrefPubMedGoogle Scholar
  • 73 Nagy B, Tóth T, Rigó Jr J, Karádi I, Romics L, Papp Z. Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women.  Clin Genet. 1998;  53(6) 478-481
    CrossrefPubMedGoogle Scholar
  • 74 Rigó Jr J, Nagy B, Fintor L et al.. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase.  Hypertens Pregnancy. 2000;  19(2) 163-172
    CrossrefPubMedGoogle Scholar
  • 75 Kupferminc M J, Fait G, Many A, Gordon D, Eldor A, Lessing J B. Severe preeclampsia and high frequency of genetic thrombophilic mutations.  Obstet Gynecol. 2000;  96(1) 45-49
    CrossrefPubMedGoogle Scholar
  • 76 Grandone E, Margaglione M, Colaizzo D et al.. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia.  Thromb Haemost. 1997;  77(6) 1052-1054
    PubMedGoogle Scholar
  • 77 Morrison E R, Miedzybrodzka Z H, Campbell D M et al.. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review.  Thromb Haemost. 2002;  87(5) 779-785
    PubMedGoogle Scholar
  • 78 Kosmas I P, Tatsioni A, Ioannidis J P. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis.  J Hypertens. 2003;  21(7) 1221-1228
    CrossrefPubMedGoogle Scholar
  • 79 Dekker G A, de Vries J I, Doelitzsch P M et al.. Underlying disorders associated with severe early-onset preeclampsia.  Am J Obstet Gynecol. 1995;  173(4) 1042-1048
    CrossrefPubMedGoogle Scholar
  • 80 De Groot C J, Bloemenkamp K W, Duvekot E J et al.. Preeclampsia and genetic risk factors for thrombosis: a case-control study.  Am J Obstet Gynecol. 1999;  181(4) 975-980
    CrossrefPubMedGoogle Scholar
  • 81 Livingston J C, Barton J R, Park V, Haddad B, Phillips O, Sibai B M. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia.  Am J Obstet Gynecol. 2001;  185(1) 153-157
    CrossrefPubMedGoogle Scholar
  • 82 O'Shaughnessy K M, Fu B, Ferraro F, Lewis I, Downing S, Morris N H. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort.  Hypertension. 1999;  33(6) 1338-1341
    PubMedGoogle Scholar
  • 83 Kim Y J, Williamson R A, Murray J C et al.. Genetic susceptibility to preeclampsia: roles of cytosineto-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine beta-synthase, and factor V Leiden mutation.  Am J Obstet Gynecol. 2001;  184(6) 1211-1217
    CrossrefPubMedGoogle Scholar
  • 84 Laivuori H, Kaaja R, Ylikorkala O, Hiltunen T, Kontula K. 677 C—>T polymorphism of the methylenetetrahydrofolate reductase gene and preeclampsia.  Obstet Gynecol. 2000;  96(2) 277-280
    CrossrefPubMedGoogle Scholar
  • 85 van Pampus M G, Koopman M M, Wolf H, Büller H R, Prins M H, van den Ende A. Lipoprotein(a) concentrations in women with a history of severe preeclampsia—a case control study.  Thromb Haemost. 1999;  82(1) 10-13
    PubMedGoogle Scholar
  • 86 Bar J, Harell D, Bardin R et al.. The elevated plasma lipoprotein(a) concentrations in preeclampsia do not precede the development of the disorder.  Thromb Res. 2002;  105(1) 19-23
    CrossrefPubMedGoogle Scholar
  • 87 Facchinetti F, Marozio L, Frusca T et al.. Maternal thrombophilia and the risk of recurrence of preeclampsia.  Am J Obstet Gynecol. 2009;  200(1) 46.e1-5
    PubMedGoogle Scholar
  • 88 van Rijn B B, Hoeks L B, Bots M L, Franx A, Bruinse H W. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia.  Am J Obstet Gynecol. 2006;  195(3) 723-728
    CrossrefPubMedGoogle Scholar
  • 89 Sibai B M, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis.  Am J Obstet Gynecol. 1986;  155(5) 1011-1016
    CrossrefPubMedGoogle Scholar
  • 90 Romo A, Carceller R, Tobajas J. Intrauterine growth retardation (IUGR): epidemiology and etiology.  Pediatr Endocrinol Rev. 2009;  6(Suppl 3) 332-336
    PubMedGoogle Scholar
  • 91 Martinelli P, Grandone E, Colaizzo D et al.. Familial thrombophilia and the occurrence of fetal growth restriction.  Haematologica. 2001;  86(4) 428-431
    PubMedGoogle Scholar
  • 92 Kupferminc M J, Many A, Bar-Am A, Lessing J B, Ascher-Landsberg J. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia.  BJOG. 2002;  109 1373-1376
    PubMedGoogle Scholar
  • 93 Grandone E, Margaglione M, Colaizzo D et al.. Lower birth-weight in neonates of mothers carrying factor V G1691A and factor II A(20210) mutations.  Haematologica. 2002;  87(2) 177-181
    PubMedGoogle Scholar
  • 94 de Vries J I, Dekker G A, Huijgens P C, Jakobs C, Blomberg B M, van Geijn H P. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies.  Br J Obstet Gynaecol. 1997;  104(11) 1248-1254
    CrossrefPubMedGoogle Scholar
  • 95 Lindqvist P G, Svensson P J, Marsaál K, Grennert L, Luterkort M, Dahlbäck B. Activated protein C resistance (FV:Q506) and pregnancy.  Thromb Haemost. 1999;  81(4) 532-537
    PubMedGoogle Scholar
  • 96 Infante-Rivard C, Rivard G E, Yotov W V et al.. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction.  N Engl J Med. 2002;  347(1) 19-25
    CrossrefPubMedGoogle Scholar
  • 97 McCowan L M, Craigie S, Taylor R S, Ward C, McLintock C, North R A. Inherited thrombophilias are not increased in “idiopathic” small-for-gestational-age pregnancies.  Am J Obstet Gynecol. 2003;  188(4) 981-985
    CrossrefPubMedGoogle Scholar
  • 98 Dudding T E, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis.  Thromb Haemost. 2004;  91 700-711
    PubMedGoogle Scholar
  • 99 Howley H E, Walker M, Rodger M A. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction.  Am J Obstet Gynecol. 2005;  192(3) 694-708
    CrossrefPubMedGoogle Scholar
  • 100 Conard J, Horellou M H, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women.  Thromb Haemost. 1990;  63(2) 319-320
    PubMedGoogle Scholar
  • 101 Leeda M, Riyazi N, de Vries J I, Jakobs C, van Geijn H P, Dekker G A. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction.  Am J Obstet Gynecol. 1998;  179(1) 135-139
    CrossrefPubMedGoogle Scholar
  • 102 Clark P, Walker I D, Greer I. Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight.  Lancet. 1999;  353(9149) 292-293
    PubMedGoogle Scholar
  • 103 Vollset S E, Refsum H, Irgens L M et al.. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study.  Am J Clin Nutr. 2000;  71(4) 962-968
    PubMedGoogle Scholar
  • 104 Grandone E, Colaizzo D, Vecchione G et al.. Homocysteine levels in amniotic fluid. Relationship with birth-weight.  Thromb Haemost. 2006;  95(4) 625-628
    PubMedGoogle Scholar
  • 105 Ananth C V, Smulian J C, Vintzileos A M. Incidence of placental abruption in relation to cigarette smoking and hypertensive disorders during pregnancy: a meta-analysis of observational studies.  Obstet Gynecol. 1999;  93(4) 622-628
    CrossrefPubMedGoogle Scholar
  • 106 Addis A, Moretti M E, Ahmed Syed F, Einarson T R, Koren G. Fetal effects of cocaine: an updated meta-analysis.  Reprod Toxicol. 2001;  15(4) 341-369
    CrossrefPubMedGoogle Scholar
  • 107 van der Molen E F, Verbruggen B, Novakova I, Eskes T K, Monnens L A, Blom H J. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy.  BJOG. 2000;  107 785-791
    CrossrefPubMedGoogle Scholar
  • 108 Dizon-Townson D S, Meline L, Nelson L M, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction.  Am J Obstet Gynecol. 1997;  177(2) 402-405
    CrossrefPubMedGoogle Scholar
  • 109 Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae.  Am J Obstet Gynecol. 1998;  179(6 Pt 1) 1565-1567
    CrossrefPubMedGoogle Scholar
  • 110 Facchinetti F, Marozio L, Grandone E, Pizzi C, Volpe A, Benedetto C. Thrombophilic mutations are a main risk factor for placental abruption.  Haematologica. 2003;  88(7) 785-788
    PubMedGoogle Scholar
  • 111 Procházka M, Happach C, Marsál K, Dahlbäck B, Lindqvist P G, Factor V. Leiden in pregnancies complicated by placental abruption.  BJOG. 2003;  110 462-466
    PubMedGoogle Scholar
  • 112 de Vries J I, Dekker G A, Huijgens P C, Jakobs C, Blomberg B M, van Geijn H P. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies.  Br J Obstet Gynaecol. 1997;  104(11) 1248-1254
    CrossrefPubMedGoogle Scholar
  • 113 Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.  Eur J Obstet Gynecol Reprod Biol. 2002;  101(1) 6-14
    CrossrefPubMedGoogle Scholar
  • 114 Goddijn-Wessel T A, Wouters M G, van de Molen E F et al.. Hyperhomocysteinemia: a risk factor for placental abruption or infarction.  Eur J Obstet Gynecol Reprod Biol. 1996;  66(1) 23-29
    CrossrefPubMedGoogle Scholar
  • 115 Chan W S, Anand S, Ginsberg J S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature.  Arch Intern Med. 2000;  160(2) 191-196
    CrossrefPubMedGoogle Scholar
  • 116 Orme M L, Lewis P J, de Swiet M et al.. May mothers given warfarin breast-feed their infants?.  BMJ. 1977;  1(6076) 1564-1565
    CrossrefPubMedGoogle Scholar
  • 117 Bowles L, Cohen H. Inherited thrombophilias and anticoagulation in pregnancy.  Best Pract Res Clin Obstet Gynaecol. 2003;  17(3) 471-489
    CrossrefPubMedGoogle Scholar
  • 118 Greer I A. Exploring the role of low-molecular-weight heparins in pregnancy.  Semin Thromb Hemost. 2002;  28(Suppl 3) 25-31
    PubMedGoogle Scholar
  • 119 Royal College of Obstetricians and Gynaecologists (RCOG) .Thromboprophylaxis during Pregnancy, Labour and after Vaginal Delivery. Guideline no. 37. London, United Kingdom; RCOG Press 2004
    PubMedGoogle Scholar
  • 120 Lussana F, Dentali F, Abbate R et al.. Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines by the Italian Society of Haemostasis and Thrombosis.  Thromb Res. 2009 August 10 (Epub ahead of print); 
    PubMedGoogle Scholar
  • 121 Gerhardt A, Scharf R E, Beckmann M W et al.. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.  N Engl J Med. 2000;  342(6) 374-380
    CrossrefPubMedGoogle Scholar
  • 122 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J S. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.  Thromb Haemost. 2000;  83(5) 693-697
    PubMedGoogle Scholar
  • 123 Ogueh O, Chen M F, Spurll G, Benjamin A. Outcome of pregnancy in women with hereditary thrombophilia.  Int J Gynaecol Obstet. 2001;  74(3) 247-253
    CrossrefPubMedGoogle Scholar
  • 124 Kupferminc M J, Fait G, Many A et al.. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias.  Hypertens Pregnancy. 2001;  20(1) 35-44
    CrossrefPubMedGoogle Scholar
  • 125 Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. LIVE-ENOX Investigators . Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study.  J Thromb Haemost. 2005;  3(2) 227-229
    CrossrefPubMedGoogle Scholar
  • 126 Grandone E, Brancaccio V, Colaizzo D et al.. Preventing adverse obstetric outcomes in women with genetic thrombophilia.  Fertil Steril. 2002;  78(2) 371-375
    CrossrefPubMedGoogle Scholar
  • 127 Rey E, Garneau P, David M et al.. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.  J Thromb Haemost. 2009;  7(1) 58-64
    CrossrefPubMedGoogle Scholar
  • 128 Grandone E, De Stefano V, Rossi E, Cappucci F, Colaizzo D, Margaglione M. Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants.  Blood Coagul Fibrinolysis. 2008;  19(3) 226-230
    CrossrefPubMedGoogle Scholar
  • 129 Walker I D, Kujovich J L, Greer I A et al.. The use of LMWH in pregnancies at risk: new evidence or perception?.  J Thromb Haemost. 2005;  3(4) 778-793
    CrossrefPubMedGoogle Scholar

Elvira GrandoneM.D. 

Atherosclerosis and Thrombosis Unit, I.R.C.C.S. “Casa Sollievo della Sofferenza,” Poliambulatorio Giovanni Paolo II

Viale Padre Pio, S. Giovanni R. (FG), Italy

Email: e.grandone@operapadrepio.it

      >